These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25304530)

  • 41. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What influences placebo and nocebo responses in Parkinson's disease?
    Witek N; Stebbins GT; Goetz CG
    Mov Disord; 2018 Aug; 33(8):1204-1212. PubMed ID: 30132980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Electroconvulsive therapy (ECT) in Parkinson's disease: ECS and dopamine enhancement.
    Cumper SK; Ahle GM; Liebman LS; Kellner CH
    J ECT; 2014 Jun; 30(2):122-4. PubMed ID: 24810775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
    Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
    Elsworth JD; Roth RH
    Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain.
    van den Berge SA; van Strien ME; Korecka JA; Dijkstra AA; Sluijs JA; Kooijman L; Eggers R; De Filippis L; Vescovi AL; Verhaagen J; van de Berg WD; Hol EM
    Brain; 2011 Nov; 134(Pt 11):3249-63. PubMed ID: 22075520
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Milestones in Parkinson's disease therapeutics.
    Rascol O; Lozano A; Stern M; Poewe W
    Mov Disord; 2011 May; 26(6):1072-82. PubMed ID: 21626552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI.
    MacDonald PA; MacDonald AA; Seergobin KN; Tamjeedi R; Ganjavi H; Provost JS; Monchi O
    Brain; 2011 May; 134(Pt 5):1447-63. PubMed ID: 21596772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies.
    Diederich NJ; Goetz CG
    Neurology; 2008 Aug; 71(9):677-84. PubMed ID: 18725593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Placebo and nocebo effects: a complex interplay between psychological factors and neurochemical networks.
    Frisaldi E; Piedimonte A; Benedetti F
    Am J Clin Hypn; 2015 Jan; 57(3):267-84. PubMed ID: 25928679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breaking away from dopamine deficiency: an essential new direction for Parkinson's disease.
    Willis GL; Moore C; Armstrong SM
    Rev Neurosci; 2012; 23(4):403-28. PubMed ID: 23089606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How placebos change the patient's brain.
    Benedetti F; Carlino E; Pollo A
    Neuropsychopharmacology; 2011 Jan; 36(1):339-54. PubMed ID: 20592717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular mechanisms of placebo responses in humans.
    Peciña M; Zubieta JK
    Mol Psychiatry; 2015 Apr; 20(4):416-23. PubMed ID: 25510510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding the placebo effect. Part 2: underlying psychological & neurobiological processes.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Jun; 46(6):15-8. PubMed ID: 18595454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nature of the placebo and nocebo effect in relation to functional neurologic disorders.
    Carlino E; Piedimonte A; Benedetti F
    Handb Clin Neurol; 2016; 139():597-606. PubMed ID: 27719874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The placebo effect: From concepts to genes.
    Colagiuri B; Schenk LA; Kessler MD; Dorsey SG; Colloca L
    Neuroscience; 2015 Oct; 307():171-90. PubMed ID: 26272535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.